+45.2%
ASML vs MRNA
+787.6%
-742.4%
-31.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.4% | -7.0% | +4.5% | -2.3% |
| 7D | +10.4% | -4.2% | +14.5% | +10.4% |
| 30D | -12.7% | +7.0% | -19.7% | -12.7% |
| 3M | -17.2% | +263.4% | -280.5% | -17.8% |
| 6M | -1.3% | +334.3% | -335.6% | -7.5% |
| YTD | +40.8% | +684.5% | -643.7% | +22.3% |
| 1Y | +45.2% | +766.2% | -720.9% | +23.9% |
| All | +45.2% | +787.6% | -742.4% | +23.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling